Molina Healthcare reports on July 22 with short sellers adding pressure even as the stock pulls back from recent highs — a setup that sharpens the stakes on what the print actually delivers.
Short interest has climbed nearly 20% over the past month, reaching 6.1% of the free float. That's a meaningful build. The weekly pace has accelerated too, with SI up roughly 8% in the past five days alone. Despite that rise, the borrow market remains extremely loose — availability runs at 1,554%, meaning shares to lend dwarf those already shorted by a factor of more than fifteen. Cost to borrow has also eased sharply, falling around 24% from a month ago to just 0.37%. The lending market is not signalling any squeeze pressure; the growing short position is being funded cheaply and easily.
Options positioning has actually shifted in a more constructive direction, telling a different story from the short interest build. The put/call ratio has dropped to 0.99, now running about 1.25 standard deviations below its 20-day average of 1.06 — the opposite of defensive. That's a notable shift: for most of June and into early July, the PCR sat consistently above 1.05. The recent move lower coincides with the stock's 12.6% monthly rally, suggesting options traders are less inclined to hedge than they were before the run-up. The stock itself has given back 3.4% over the past week, pulling from around $241 to $225, though it remains well up on the month.
The central tension heading into the print is the one flagged in prior coverage: MOH still trades above the consensus mean price target of roughly $211, with the bulk of the Street parked at Hold or equivalent. The bull case rests on Medicaid segment resilience and Medicare expansion potential. The bear case — most clearly articulated by Barclays, which holds an Underweight with a $184 target — focuses on uncertain Medicaid reimbursement rates, membership pressure from eligibility redeterminations, and a Florida CMS contract that carries execution risk. Most firms that raised targets this week did so without upgrading their ratings, which means the Street has acknowledged the tape move without endorsing the valuation. EPS momentum scores are strong — ranking in the 87th and 91st percentile on 30- and 90-day measures — and the analyst recommendation divergence score remains in the 95th percentile, reflecting how wide the gap is between where the stock trades and where most analysts are comfortable. BlackRock added over 2.4 million shares as recently as June 30, a meaningful institutional vote of confidence, though that predates the latest leg of the rally.
The July 22 print will test whether the operational delivery — particularly on Medicaid margins and membership trends — is strong enough to justify a stock that the consensus still formally regards as fully valued or beyond.
See the live data behind this article on ORTEX.
Open MOH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
